Allergies to grass pollen affects about 20% of the population worldwide. In the last few decades, the South American grass Cortaderia selloana (CS, Pampas grass) has expanded worldwide in a variety of countries including the USA, Australia and Western Europe. In many of these locations, CS has strikingly spread and has now been classified an invasive species. Many pernicious consequences of CS have been reported for local biodiversity, landscape and structures. However, the effect on human health has not been studied. To investigate this issue, we have chosen a European region on the northern cost of Spain where CS spread is overwhelming, Cantabria. We obtained CS pollen extract and analysed the allergenic reaction of 98 patients that were allergic to pollen of local grasses. We determined the skin reaction and the presence of specific IgE antibodies (sIgE) to CS or to a typical autochthonous grass, Phleum pratense. We also compared the seasonal symptoms with reported grass pollen counts in the area. The results strongly suggest that CS can cause respiratory allergies at a similar extent to the local grasses. Given that CS pollinises later than the local grasses, this would extend the period of grass allergies in the region for about three months every year, as stated by most of the patients. This is the first study reported on the effects of the striking expansion of CS on human health. Considering the strong impact that respiratory allergies have on the population, our results suggest that CS can currently constitute a relevant environmental health issue.
Mite-induced allergic respiratory diseases are a major global health concern, and evidence on allergen immunotherapy (AIT) combining allergens from different mite families remains limited, particularly for Lepidoglyphus destructor. This study evaluated the effectiveness and safety of subcutaneous allergen immunotherapy containing glutaraldehydempolymerized extracts of Dermatophagoides pteronyssinus, Dermatophagoides farinae, and L. destructor in mite-allergic patients in Spain. This retrospective multicenter study included 199 patients with allergic rhinoconjunctivitis, with or without asthma. Effectiveness outcomes included combined symptom and medication scores (CSMS), symptom scores, and medication use. Safety outcomes included adverse reactions. Mixed models for repeated measures showed significant improvements in rhinoconjunctivitis and asthma outcomes (all p < 0.001). Adjusted LS-mean rhinoconjunctivitis CSMS decreased by 50.7% at T1 and 76.1% at T4; symptom and medication scores decreased by 85.3% and 69.3%, respectively, at T4. Asthma CSMS decreased by 43.1% at T1 and 89.0% at T5, while symptom and medication scores decreased by 93.4% and 88.5%, respectively. Similar patterns were observed in children. No systemic reactions occurred. Twenty mild local reactions were recorded in 17 patients (8.5%), corresponding to an estimated rate of 0.32% across 6169 injections. This AIT was associated with sustained clinical improvement and a favorable safety profile in adults and children.
Allergen immunotherapy combining mite and grass pollen extracts may offer a practical option for polysensitized patients, but real-world evidence remains limited. This multicentre, retrospective, non-controlled, longitudinal study evaluated the effectiveness and safety of two subcutaneous immunotherapy formulations containing glutaraldehyde-polymerized Dermatophagoides spp./grass pollen or Dermatophagoides pteronyssinus/grass pollen extracts. Rhinoconjunctivitis and asthma symptom and medication scores were assessed annually for up to five years using mixed models for repeated measures and complementary non-parametric analyses; adverse reactions were also recorded. The two treatment cohorts included 105 and 137 patients, respectively. Both formulations were associated with significant reductions in rhinoconjunctivitis and asthma-related scores from the first year of treatment. For the Dermatophagoides spp./grass pollen formulation, the Rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS) and Asthma Combined Symptom and Medication Score (ACSMS) least-squares means decreased by 47.3% and 41.9% at T1 and by 53.0% and 55.1% at T2, respectively. For Dermatophagoides pteronyssinus/grass pollen, reductions at T1 were 51.6% and 58.7%, with improvements generally maintained during follow-up. Adverse reactions were infrequent and predominantly local; two systemic reactions occurred in the Dermatophagoides spp./grass pollen cohort. These findings suggest that, in selected patients treated under routine clinical practice conditions, both formulations were associated with reductions in symptom and medication scores and showed an acceptable safety profile. However, due to the retrospective uncontrolled design, these reductions cannot be attributed solely to immunotherapy, and prospective controlled studies are needed to confirm these observations.